Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

Completed · Phase 1

Conditions studied: Mucopolysaccharidosis VI

In brief

The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.

Key facts

Study ID
NCT00048620
Run by
BioMarin Pharmaceutical
Starts
2000-09-01
Expected to finish
2005-11-01
Last updated by the study team
2006-11-03

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.